Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Jan 31, 2019 → May 11, 2022
NCT ID
NCT03497689About Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil is a approved stage product being developed by United Therapeutics for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT03497689. Target conditions include Pulmonary Arterial Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Arterial Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03497689 | Approved | Completed |
Competing Products
20 competing products in Pulmonary Arterial Hypertension